CDKN2A and metastatic neoplasm: This limited or latent FdCyd-induced increase in the proportion of p16-expressing VIM+ CTCs, if verified by larger studies, may have biological and clinical implications given the importance of mesenchymal-associated characteristics such as enhanced motility and invasion in metastatic disease, as well as the apparent prognostic value of mesenchymalCTCs suggested by the recent studies [24–27].